ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 935

Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis

Yasushi Kondo1, Yuko Kaneko2,3, Hiroaki Sugiura4, Shunsuke Matsumoto4, Naoshi Nishina3, Masahiro Jinzaki4 and Tsutomu Takeuchi1, 1Keio University School of Medcine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 2Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 4Department of Radiology, Keio University School of Medicine, Tokyo, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bone, IL-6, MRI and cytokines

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Imaging of Rheumatic Diseases I: Advanced Imaging in RA and Spondyloarthritides

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Plasma cytokines include tumour necrosis factor (TNF)-ƒ¿, interleukin (IL)-1 and IL-6 play important roles in the pathogenesis of rheumatoid arthritis (RA) causing not only joint inflammation but also joint destruction. On the other hand, magnetic resonance imaging (MRI) can visualize fine distinction in the inflamed joint sensitively, and bone erosions on MRI are well relevant with prospective tangible erosions on X-ray. The aim of this study is to examine the relationship of pretreatment plasma inflammatory cytokines with MRI bone erosion progression in patients with RA patients.

Methods: We enrolled 89 newly diagnosed, untreated patients with RA. Contrast MRIs of the dominant hand and X-ray of hands and feet at baseline and 1 year later were performed. MR images were scored according to the latest OMERACT rheumatoid arthritis magnetic imaging score (RAMRIS) for synovitis, osteitis, bone erosions. Changes in MRI erosion scores (DRAMRIS erosion) from baseline to 1 year were calculated. X-ray were also assessed using the modified total Sharp score (mTSS). Plasma levels of ten cytokines were measured by electrochemiluminescence assay.

Results: The median age and symptom duration were 58 years and 3.2 months, respectively. The mean DAS28 decreased from 4.8 at baseline to 2.4 at 1 year. Progression in bone erosion were observed more frequently in MRI than in X-ray (54% in MRI vs 21% in X-ray, p = 0.005). Multiple linear regression model with baseline DAS28, seropositivity (positive for anti-CCP or RF), CRP and cytokines including IL-6, VEGF and IL-1ƒÀ as an independent variable revealed that baseline IL-6 levels and seropositivity were independent predictive factors for 1 year DRAMRIS erosion score. Receiver operating characteristic curve found the baseline IL-6 level of 7.6 pg/ml discriminated MRI erosion progression during 1 year with AUC of 0.82 with sensitivity of 69% and specificity of 95% (figure 1). We divided the patients into 4 groups (high, moderate-high, moderate-low and low) according to baseline IL-6 levels. The RAMRIS erosion progression was significantly dependent on baseline IL-6 concentration (p<0.001). While erosions in MRI significantly increased in high and moderate-high IL-6 groups (p < 0.05), mod-low and low IL-6 group showed slight improvement of MRI erosion at 1 year (figure 2)

Conclusion: In newly diagnosed, untreated RA patients, baseline plasma IL-6 levels predict 1-year MRI bone erosion progression in patients with RA.   Figure 1

  Figure 2

       


Disclosure: Y. Kondo, None; Y. Kaneko, None; H. Sugiura, None; S. Matsumoto, None; N. Nishina, None; M. Jinzaki, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina N, Jinzaki M, Takeuchi T. Pretreatment Plasma IL-6 Levels Are Responsible for Bone Erosion Progression on Magnetic Resonance Imaging in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/pretreatment-plasma-il-6-levels-are-responsible-for-bone-erosion-progression-on-magnetic-resonance-imaging-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pretreatment-plasma-il-6-levels-are-responsible-for-bone-erosion-progression-on-magnetic-resonance-imaging-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology